TITLE

Does a Calculated 'NAFLD Fibrosis Score' Reliably Negate the Need for Liver Biopsy in Patients Undergoing Bariatric Surgery?

AUTHOR(S)
Simo, Kerri; McKillop, Iain; McMillan, Matthew; Ahrens, William; Walters, Amanda; Thompson, Kyle; Kuwada, Timothy; Martinie, John; Iannitti, David; Gersin, Keith; Sindram, David
PUB. DATE
January 2014
SOURCE
Obesity Surgery;Jan2014, Vol. 24 Issue 1, p15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Nonalcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver disease in the USA. Biopsy has been the standard for determining fibrosis but is invasive, costly, and associated with risk. Previous studies report a calculated 'NAFLD fibrosis scores' (cNFS) as a means to overcome the need for biopsy. We compared cNFS versus biopsy-pathological scoring for patients undergoing bariatric surgery. Methods: We retrospectively reviewed patients with available preoperative labs and patient information undergoing Roux-en-Y gastric bypass (RYGBP) surgery at a single institution over a 5.5-year period. Biopsy samples were blind scored by a single hepatopathologist and compared with scores calculated using a previously reported cNFS. Results: Of the 225 patients that met the inclusion criteria, the mean body mass index was 44.6 ± 5.4 kg/m and 85 % were female. Using the cNFS, 39.6 % of patients were categorized into low fibrosis, 52 % indeterminate, and 8.4 % high fibrosis groups. Analysis of fibrosis by pathology scoring demonstrated 2 of 89 (2.2 %) and 7 of 110 (3.4 %) had significant fibrosis in the low and intermediate groups, respectively. Conversely, in the high fibrosis group calculated by cNFS, only 6 of 19 (31.6 %) exhibited significant fibrosis by pathology scoring. Conclusions: No definitive model for accurately predicting presence of NAFLD and fibrosis currently exits. Furthermore, under no circumstances should a clinical 'NAFLD fibrosis score' replace liver biopsy at this time for RYGBP patients.
ACCESSION #
93463826

 

Related Articles

  • Cost-utility analysis of nonalcoholic steatohepatitis screening. Zhang, Eric; Wartelle-Bladou, Claire; Lepanto, Luigi; Lachaine, Jean; Cloutier, Guy; Tang, An // European Radiology;Nov2015, Vol. 25 Issue 11, p3282 

    Objectives: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. No studies have examined the cost-effectiveness of screening its advanced form, nonalcoholic steatohepatitis (NASH).Methods: We performed a cost-utility analysis...

  • Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Praveenraj, Palanivelu; Gomes, Rachel; Kumar, Saravana; Karthikeyan, Purushothaman; Shankar, Annapoorni; Parthasarathi, Ramakrishnan; Senthilnathan, Palanisamy; Rajapandian, Subbiah; Palanivelu, Chinnusamy // Obesity Surgery;Nov2015, Vol. 25 Issue 11, p2078 

    Background: Numerous studies worldwide have identified a high prevalence of non-alcoholic fatty liver disease (NAFLD) among morbidly obese subjects. Several predictors have been found to be associated with NAFLD and its histological high-risk components. Similar data from India is lacking. We...

  • Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Tapper, Elliot B; Sengupta, Neil; Hunink, M G Myriam; Afdhal, Nezam H; Lai, Michelle // American Journal of Gastroenterology;Sep2015, Vol. 110 Issue 9, p1298 

    OBJECTIVES:The risk of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is traditionally assessed with a liver biopsy, which is both costly and associated with adverse events.METHODS:We sought to compare the cost-effectiveness of four different strategies to assess fibrosis risk in...

  • The role of active brown adipose tissue in human metabolism. Ozguven, Salih; Ones, Tunc; Yilmaz, Yusuf; Turoglu, H.; Imeryuz, Nese // European Journal of Nuclear Medicine & Molecular Imaging;Feb2016, Vol. 43 Issue 2, p355 

    Purpose: The presence of activated brown adipose tissue (ABAT) has been associated with a reduced risk of obesity in adults. We aimed to investigate whether the presence of ABAT in patients undergoing F-FDG PET/CT examinations was related to blood lipid profiles, liver function, and the...

  • A beverage tax would cut the fat. Daines, Richard F. // Crain's New York Business;3/15/2010, Vol. 26 Issue 11, p11 

    The article presents the author's opinion on the possible advantages of a beverage tax in New York. The author explains that sugary drinks have been shown to cause obesity, and argues that taxing such beverages could help decrease obesity and shift consumers towards lower-calorie beverages. The...

  • Hospitals Ratchet Up their Obesity Battle. ASTON, GERI // Hospitals & Health Networks;Jul2014, Vol. 88 Issue 7, p55 

    The article discusses the role of hospitals in the battle of obesity in the U.S. where more than one-third of adults and 17% of children are obese. It notes the risks of obesity in increasing other serious health problems including heart disease, diabetes and stroke. It highlights the medical...

  • Non-Alcoholic Steatohepatitis: Effect of Roux-en-Y Gastric Bypass Surgery. Barker, Kevin B.; Palekar, Nicole A.; Bowers, Steven P.; Goldberg, Joel E.; Pulcini, Joseph P.; Harrison, Stephen A. // American Journal of Gastroenterology;Feb2006, Vol. 101 Issue 2, p368 

    OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is an increasingly prevalent problem. Treatment options are still under investigation. The primary aim of the study was to determine whether weight loss, achieved through Roux-en-Y gastric bypass (RYGBP), improved histopathology in obese patients...

  • Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. Shores, Nathan; Link, Kerry; Fernandez, Adolfo; Geisinger, Kim; Davis, Matt; Nguyen, Tam; Sawyer, Janet; Rudel, Larry; Shores, Nathan J; Geisinger, Kim R // Digestive Diseases & Sciences;Jul2011, Vol. 56 Issue 7, p2145 

    Background: Hepatic macrosteatosis (HMS) is prevalent among high BMI patients, but a lack of validation of non-invasive measures of liver fat hampers non-alcoholic liver disease (NAFLD) investigation in general. Recent work suggests BMI adjusted, non-contrasted computed tomography...

  • Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. Losekann, Alexandre; Weston, Antonio C.; de Mattos, Angelo A.; Tovo, Cristiane V.; de Carli, Luis A.; Espindola, Marilia B.; Pioner, Sergio R.; Coral, Gabriela P. // International Journal of Molecular Sciences;2015, Vol. 16 Issue 10, p25552 

    The aim was to investigate the prevalence of non-alcoholic steatohepatitis (NASH) and risk factors for hepatic fibrosis in morbidly obese patients submitted to bariatric surgery. This retrospective study recruited all patients submitted to bariatric surgery from January 2007 to December 2012 at...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics